RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) on January 5 and set a price target of $19.00. The company’s shares closed yesterday at $17.30.
According to TipRanks, Renza is a 3-star analyst with an average return of 0.9% and a 38.12% success rate. Renza covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Prometheus Biosciences, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $19.36 average price target, an 11.91% upside from current levels. In a report released on January 3, Guggenheim also upgraded the stock to a Buy with a $22.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $28.06 and a one-year low of $12.24. Currently, ACADIA Pharmaceuticals has an average volume of 1.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Read More on ACAD: